Shield Thera Regulatory News (STX)

Shield Therapeutics plc

("Shield" or the "Group")

Appointment of Two Non-Executive Directors

London, UK, 10 May 2021: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with an initial focus on addressing iron deficiency, is pleased to announce the appointment of Fabiana Lacerca-Allen and Anders Lundstrom, as Independent Non-Executive Directors of the Company with immediate effect.

Mrs Lacerca-Allen is currently Senior Vice President, Chief Compliance Officer at Aimmune Therapeutics based in San Francisco, California (a Nestlé Health Science Corporation since October 2020). She brings to Shield extensive experience in compliance having started and implemented compliance programmes at several major pharmaceutical companies including Merck, Sharp & Dohme, Bristol-Myers Squibb Company, Mylan Laboratories and Elan Pharmaceuticals. Mrs Lacerca-Allen was also a non-executive director at ArthroCare Corporation, a publicly traded company in the medical device sector prior to its acquisition by Smith & Nephew in 2014. Fabiana holds a masters in law from the University of California, a Doctor in Law and a Bachelor in Law from the Universidad de Buenos Aires and is the recipient of several international recognitions and has been published extensively in areas of leadership and compliance. Mrs Lacerca-Allen will become a member of the Group's Audit Committee.

Mr Lundstrom is currently Executive Vice President and Chief Commercial Officer at Banner Life Sciences where he is planning and executing a US launch of a novel fumerate, Bafiertam, for the treatment of Multiple Sclerosis. He has over 25 years' experience in the pharmaceutical industry and has held senior commercial roles in AstraZeneca, Biogen, Orexo AB, where he was President and CEO from 2011 to 2013, and EMD Serono. Mr Lundstrom will join the Remuneration Committee, replacing Rolf Hoffmann who, as previously announced, is not seeking re-election at the next Annual General Meeting.

Hans Peter Hasler, Chairman of Shield Therapeutics plc, said: "I am delighted to welcome both Fabiana and Anders to the Board of Shield. Fabiana's extensive experience and knowledge of the pharmaceutical industry and her US compliance experience along with Anders' extensive experience and knowledge of the pharmaceutical industry and his US commercialisation experience will significantly strengthen the current Board structure whilst Shield prepares for the US launch of Accrufer®.

We would like to take this opportunity to thank Rolf for all that he has contributed to Shield through his knowledge, commitment and support over these last 3 years and we wish him the very best of luck."

Regulatory Disclosures

The following disclosures are required regarding Fabiana's appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Maria Fabiana Lacerca-Allen, aged 54.

Schedule of directorships and previous directorships (resigned within the last five years):

No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Fabiana Lacerca-Allen. 

The following disclosures are required regarding Anders' appointment pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:

Full name and age: Karl Anders Lundstrom, aged 58.

Schedule of directorships and previous directorships (resigned within the last five years):

No further disclosure is required under AIM Rule 17 and paragraph (g) to Schedule Two of the AIM Rules with respect to Anders Lundstrom. 

For further information, please contact:

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru® /Accrufer® (ferric maltol), a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia.

Shield's lead product, Feraccru®/Accrufer®, has been approved for use in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid-2030s. The Group plans to launch Accrufer® in the US during 2021 through a highly experienced sales and marketing team. Feraccru® is already being commercialised in the UK and European Union by Norgine B.V., who also have the marketing rights in Australia and New Zealand. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialisation of Feraccru®/Accrufer® in China, Hong Kong, Macau and Taiwan. 

For more information, please visit www.shieldtherapeutics.com. Follow Shield on Twitter @ShieldTx